The Company is engaged in the discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules.


Updates from The Motley Fool

Latest updates on Ariad Pharmaceuticals from Fool.com.


Stock Performance

ARIA vs. S&P 500 | 2 Year Performance
View Interactive ARIA Charts
Sponsored by

Key Data Points

Primary metrics and data points about Ariad Pharmaceuticals.
Current Price: $8.11
Prev Close: $7.98
Open: $7.97
Bid: $7.77
Ask: $8.18
Day's Range: $7.89 - $8.24
52wk Range: $4.37 - $10.07
Volume: 6,136,555
Avg Vol 4,056,716
Market Cap: $1.54B
P/E (ttm): -6.49
EPS (ttm): -$1.23
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Ariad Pharmaceuticals.
CAPS Rating 2 out of 5
 
385 Outperform
48 Underperform
CAPS All Stars
 
51 Outperform
20 Underperform

How do you think Ariad Pharmaceuticals will perform against the market?



You pick for Ariad Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Paris Panayiotopoulos, CEO

0% Approve

Based on 2 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Ariad Pharmaceuticals.

The Company is engaged in the discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers